Experiments treating T- and B-ALL xenografts with Palbociclib and Ribociclib suggest a possible effect on CDK4/6 inhibitors, and their application in ALL patients could be a therapeutic option in the future, which remains to be studied [50]. The gene discussed is CDK4; the disease is acute lymphoblastic leukemia.